MOISES FAJARDO: Open Payments
NPI 1740683069 · CLAWSON, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,153 in 40 payments from 22 companies in 2025. Trend: 2023 $1,817 · 2024 $4,048 · 2025 $3,153
Food & beverage: $2,454Long term medical supply or device loan: $699
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $732 |
| AstraZeneca Pharmaceuticals LP | 4 | $288 |
| Amgen Inc. | 2 | $195 |
| Incyte Corporation | 2 | $179 |
| Janssen Biotech, Inc. | 3 | $146 |
| Averitas Pharma Inc. | 1 | $145 |
| JAZZ PHARMACEUTICALS INC. | 2 | $136 |
| Axsome Therapeutics, Inc. | 2 | $135 |
| Alexion Pharmaceuticals, Inc. | 1 | $126 |
| Agios Pharmaceuticals, Inc. | 1 | $125 |
Products named: KISQALI, IMDELLTRA (AMG757), QUTENZA, Auvelity, PYRUKYND, Wegovy, EPIDIOLEX, REXULTI.
Industry payments across MI — which companies pay providers there.
